Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing

PLoS Pathogens

Volumn 10, Issue 4, 2014, Pages

  Wei, Datsen George ^a   Chiang, Vicki ^a   Fyne, Elizabeth ^b   Balakrishnan, Mini ^a   Barnes, Tiffany ^a   Graupe, Michael ^a   Hesselgesser, Joseph ^a   Irrinki, Alivelu ^a   Murry, Jeffrey P ^a   Stepan, George ^a   Stray, Kirsten M ^a   Tsai, Angela ^a   Yu, Helen ^a   Spindler, Jonathan ^c   Kearney, Mary ^c   Spina, Celsa A ^d   McMahon, Deborah ^b   Lalezari, Jacob ^e   Sloan, Derek ^a   Mellors, John ^b   Geleziunas, Romas ^a   Cihlar, Tomas ^a   more..

^a GILEAD SCIENCES   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Quest Clinical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GIVINOSTAT; HISTONE DEACETYLASE; IONOMYCIN; ISOENZYME; MOCETINOSTAT; PANOBINOSTAT; PRACINOSTAT; ROMIDEPSIN; VIRUS RNA; VORINOSTAT; ANTINEOPLASTIC ANTIBIOTIC; DEPSIPEPTIDE; HISTONE DEACETYLASE INHIBITOR;

ARTICLE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL SUBPOPULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; ENZYMATIC ASSAY; EX VIVO STUDY; FLOW CYTOMETRY; GENOME ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IMMUNOCOMPETENT CELL; IN VITRO STUDY; LATENT VIRUS INFECTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYLOGENY; PROVIRUS; RNA SEQUENCE; SEQUENCE ANALYSIS; T CELL CULTURE; VIRION; VIRUS EXPRESSION; VIRUS INDUCTION; VIRUS RELEASE; VIRUS TRANSCRIPTION; BIOLOGICAL MODEL; CELL CULTURE; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGICAL MEMORY; MALE; METABOLISM; MULTICENTER STUDY; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION; VIRUS LATENCY;

ANTIBIOTICS, ANTINEOPLASTIC; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOLOGIC MEMORY; ISOENZYMES; MALE; MODELS, BIOLOGICAL; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 84901309171     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004071     Document Type: Article

References (59)

1. DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, et al. (2012) Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 379: 2429-2438.
2. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, et al. (2013) Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 381: 735-743.
3. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, et al. (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 105: 3879-3884.
4. Chun TW, Davey RT Jr, Ostrowski M, Shawn Justement J, Engel D, et al. (2000) Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 6: 757-761.
5. Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, et al. (2004) Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. PLoS Med 1: e64.
6. Siliciano JD, Siliciano RF, (2006) The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure. Curr Opin HIV AIDS 1: 121-128.
7. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, et al. (2003) Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9: 727-728.
8. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, et al. (2009) HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15: 893-900.
9. Eisele E, Siliciano RF, (2012) Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37: 377-388.
10. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, et al. (2013) Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog 9: e1003174.
11. Siliciano JD, Siliciano RF, (2013) HIV-1 eradication strategies: design and assessment. Curr Opin HIV AIDS 8: 318-325.
12. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, et al. (2009) The challenge of finding a cure for HIV infection. Science 323: 1304-1307.
13. Antiretroviral Therapy Cohort C, (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372: 293-299.
14. Smit C, Geskus R, Walker S, Sabin C, Coutinho R, et al. (2006) Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS 20: 741-749.
15. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, et al. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349: 1993-2003.
16. Coiras M, Lopez-Huertas MR, Perez-Olmeda M, Alcami J, (2009) Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs. Nat Rev Microbiol 7: 798-812.
17. Colin L, Van Lint C, (2009) Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology 6: 111.
18. Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, et al. (2006) NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J 25: 139-149.
19. Jiang G, Espeseth A, Hazuda DJ, Margolis DM, (2007) c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol 81: 10914-10923.
20. Wightman F, Ellenberg P, Churchill M, Lewin SR, (2012) HDAC inhibitors in HIV. Immunology and Cell Biology 90: 47-54.
21. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, et al. (2009) Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Research and Human Retroviruses 25: 207-212.
22. Edelstein LC, Micheva-Viteva S, Phelan BD, Dougherty JP, (2009) Short communication: activation of latent HIV type 1 gene expression by suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor approved for use to treat cutaneous T cell lymphoma. AIDS Res Hum Retroviruses 25: 883-887.
23. Matalon S, Rasmussen TA, Dinarello CA, (2011) Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir. Mol Med 17: 466-472.
24. Beliakova-Bethell N, Zhang JX, Singhania A, Lee V, Terry VH, et al. (2013) Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells. AIDS 27: 29-37.
25. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, et al. (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487: 482-485.
26. Rasmussen TA, Schmeltz Sogaard O, Brinkmann C, Wightman F, Lewin SR, et al. (2013) Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 9: 993-1001 doi:10.4161/hv.23800.
27. Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, et al. (1994) FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo) 47: 301-310.
28. Bertino EM, Otterson GA, (2011) Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs 20: 1151-1158.
29. Bosque A, Planelles V, (2009) Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells. Blood 113: 58-65.
30. Bosque A, Planelles V, (2011) Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells. Methods 53: 54-61.
31. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, et al. (2011) Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117: 5827-5834.
32. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, et al. (2002) Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 8: 718-728.
33. Istodax (romidepsin) for injection. US Prescribing Information. Celgene Corporation. Summit, NJ. Revised June 2013.
34. Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, et al. (2005) Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 43: 406-413.
35. Kearney M, Palmer S, Maldarelli F, Shao W, Polis MA, et al. (2008) Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase. AIDS 22: 497-501.
36. Kearney M, Spindler J, Shao W, Maldarelli F, Palmer S, et al. (2011) Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy. J Virol 85: 1067-1076.
37. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, et al. (2013) Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155: 540-551.
38. Furumai R, Matsuyama A, Kobashi N, Lee KH, Nishiyama M, et al. (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 62: 4916-4921.
39. Elliott J, Solomon A, Wightman F, Smith M, Palmer S, et al. (2013) The safety and effect of multiple foses of vorinostat on HIV transcription in HIV+ patients receiving cART. [Abstract 50LB]. In: 20th Conference on Retroviruses and Opportunistic Infections 3-6 March 2013. Atlanta, Georgia, United States of America.
40. Rasmussen T, CLEAR study group (2014). Panobinostat induces HIV transcription and plasma viremia in HIV patients on suppressive cART. [Abstract 438LB]. In: Conference on Retroviruses and Opportunistic Infections 3-6 March 2014. Boston, Massachusetts, United States of America.
41. Burnett JC, Lim KI, Calafi A, Rossi JJ, Schaffer DV, et al. (2010) Combinatorial latency reactivation for HIV-1 subtypes and variants. J Virol 84: 5958-5974.
42. Friedman J, Cho WK, Chu CK, Keedy KS, Archin NM, et al. (2011) Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. Journal of Virology 85: 9078-9089.
43. Bouchat S, Gatot JS, Kabeya K, Cardona C, Colin L, et al. (2012) Histone methyltransferase inhibitors induce HIV-1 recovery in resting CD4(+) T cells from HIV-1-infected HAART-treated patients. AIDS 26: 1473-1482.
44. Xing S, Bullen CK, Shroff NS, Shan L, Yang HC, et al. (2011) Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol 85: 6060-6064.
45. Xing S, Bhat S, Shroff NS, Zhang H, Lopez JA, et al. (2012) Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Antimicrob Chemother 67: 398-403.
46. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, et al. (2012) Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36: 491-501.
47. Badley AD, Sainski A, Wightman F, Lewin SR, (2013) Altering cell death pathways as an approach to cure HIV infection. Cell Death Dis 4: e718.
48. Smalls-Mantey A, Doria-Rose N, Klein R, Patamawenu A, Migueles SA, et al. (2012) Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J Virol 86: 8672-8680.
49. Bhutani D, Vaishampayan UN, (2013) Monoclonal antibodies in oncology therapeutics: present and future indications. Expert Opin Biol Ther 13: 269-282.
50. Iglesias-Ussel M, Vandergeeten C, Marchionni L, Chomont N, Romerio F, (2013) High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects. J Virol 87: 9148-9158.
51. Sweet MJ, Shakespear MR, Kamal NA, Fairlie DP, (2012) HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation. Immunol Cell Biol 90: 14-22.
52. Licciardi PV, Ververis K, Tang ML, El-Osta A, Karagiannis TC, (2013) Immunomodulatory effects of histone deacetylase inhibitors. Curr Mol Med 13: 640-647.
53. Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, et al. (2011) Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 117: 1205-1217.
54. Doherty R, O'Farrelly C, Meade KG, (2013) Epigenetic regulation of the innate immune response to LPS in bovine peripheral blood mononuclear cells (PBMC). Vet Immunol Immunopathol 154: 102-110.
55. Hara N, Alkanani AK, Dinarello CA, Zipris D, (2014) Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes. J Mol Med (Berl) 92: 93-102.
56. Alvarez-Breckenridge CA, Yu J, Price R, Wei M, Wang Y, et al. (2012) The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon. J Virol 86: 4566-4577.
57. Mombelli M, Lugrin J, Rubino I, Chanson AL, Giddey M, et al. (2011) Histone deacetylase inhibitors impair antibacterial defenses of macrophages. J Infect Dis 204: 1367-1374.
58. Kelly-Sell MJ, Kim YH, Straus S, Benoit B, Harrison C, et al. (2012) The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. Am J Hematol 87: 354-360.
59. Messi M, Giacchetto I, Nagata K, Lanzavecchia A, Natoli G, et al. (2003) Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat Immunol 4: 78-86.